October 2010
Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p9
The article presents the phase 3 and phase 2 clinical trials of several drugs studied and manufactured by pharmaceutical companies in the U.S. Drugs which include Northera and Lixisenatide in the phase 3 clinical study were discussed. It also mentions the drugs in the phase 2 trial including the BCX4208 which is tested to lower uric acid in gout patients, GSK561679 for patients with major depressive episodes, and Apoptone, a drug used for patients with prostate cancer.


Related Articles

  • Novavax Offering Raises $82M for Flu Pandemic, RSV Efforts. Osborne, Randy // BioWorld Today;9/25/2013, Vol. 24 Issue 184, p1 

    The article reports that U.S. biopharmaceutical company Novavax Inc. is preparing for the next round of trials for its influenza vaccines. Novavax is set to close a public offering of shares to raise about 87 million dollars. The company's quadrivalent seasonal and pandemic flu vaccines are...

  • Pipeline.  // Pharmaceutical Representative;May2011, Vol. 41 Issue 5, p10 

    The article presents updates on various clinical trials on drugs by pharmaceutical companies in the U.S. The Sosei Group Corp.'s NVA237, a long-acting muscarinic antagonist (LAMA) for chronic pulmonary disease (COPD) treatment, has achieved its end point in a Phase III study. Biogen Inc. has...

  • Disclosing Trial Data. Silverman, Ed // Contract Pharma;Mar2013, Vol. 15 Issue 2, p34 

    The article discusses the disclosures of patient-level data and complete study reports among drug manufacturers. It notes on the action of the U.S. Pharmaceutical Research & Manufacturers of America (PhRMA) which slammed the online petition calling drugmakers to open their accounts which has...

  • Evaluation of antidepressant activity of tramadol in mice. Tayal, Vandana; Kalra, Bhupinder Singh; Chawla, Shalini // Indian Journal of Pharmacology;Jun2008, Vol. 40 Issue 3, p129 

    Objective: To evaluate antidepressant like effect of tramadol in mice. Materials and Methods: Tramadol was administered at three different doses (10,20 and 40 mg/kg, i.p) once daily for 7 days to Swiss albino mice of either sex. The immobility period of control and drug treated mice were...

  • Arcalyst Meets Phase III Prophylaxis Endpoint.  // Bioworld Week;6/14/2010, Vol. 18 Issue 24, p4 

    The article reports on the success of IL-1 blocker Arcalyst in preventing gout attacks as shown by the Phase III study conducted by Tarrytown, New York-based Regeneron Pharmaceuticals Inc.

  • R&D Efforts Take Aim at HIV/AIDS.  // Chain Drug Review;12/7/2009, Vol. 31 Issue 21, p69 

    The article reports on the move of pharmaceutical research and biotechnology companies in the U.S. to test nearly 100 medicines and vaccines to treat or prevent HIV/AIDS and other related conditions.

  • Complex Clinical Trials are Posing New Challenges Across the Clinical Supply Chain. Miller, Jim // BioPharm International;Apr2010, Vol. 23 Issue 4, p18 

    The article reports on the impact of complex clinical trials for drugs and biologics which are mandated by the U.S. Food and Drug Administration (FDA) on pharmaceutical companies and clinical supply chain. Pharmaceutical companies are faced with the challenges of showing superiority over...

  • Gabapentin and nortriptyline combined was better than either drug alone for relief of neuropathic pain. Hughes, James // ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p5 

    The article focuses on a medical research related to effectiveness of combined gabapentin and nortriptyline in comparison to alone drug for neuropathic pain. In a clinical trial around 56 patients with neuropathy is being observed and treated with combined drugs. It concluded that gabapentin and...

  • Tricks of the Trade. Scott, Timothy // Ethical Human Psychology & Psychiatry;Summer2006, Vol. 8 Issue 2, p133 

    Before receiving Food and Drug Administration approval, drug manufacturers must conduct clinical trials of their new drugs. Although all drug studies can be manipulated, antidepressant and antipsychotic drugs are particularly vulnerable to bias. The bias is not limited to the makers of these...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics